TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive Genentech Says Phase III Trial Shows Avastin Improved PFS For Ovarian Cancer March 26, 2010
TCL Archive First shakeup In Upton Regime: Peters Moves Out As DCCP Head To Become “Special Assistant” September 30, 1977
TCL Archive Cancel Panel Activity Ceases Due To Hammer’s Death; Oxy Chairman Promoted Funding Of Research January 4, 1991
